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The high prevalence of major depressive disorder in people with Parkinson’s disease
(PD), its negative impact on health-related quality of life and the low response rate
to conventional pharmacological therapies call to seek innovative treatments. Here,
we review the new approaches for treating major depressive disorder in patients
with PD within the framework of the network model of depression. According to
this model, major depressive disorder reflects maladaptive neuronal plasticity. Non-
invasive brain stimulation (NIBS) using high frequency repetitive transcranial magnetic
stimulation (rTMS) over the prefrontal cortex has been proposed as a feasible and
effective strategy with minimal risk. The neurobiological basis of its therapeutic effect may
involve neuroplastic modifications in limbic and cognitive networks. However, the way
this networks reorganize might be strongly influenced by the environment. To address
this issue, we propose a combined strategy that includes NIBS together with cognitive
and behavioral interventions.
Keywords: Parkinson’s disease, neurostimulation, depression, cognitive and behavioral therapy, transcranial
magnetic stimulation
MAJOR DEPRESSIVE DISORDER IN PD
Prevalence and Features
Major depressive disorder is a widely distributed chronic condition. While 1-year prevalence
estimates of this entity round 5–10%, the lifetime prevalence reaches up to 15–20%. Moreover,
major depressive disorder is characterized by high relapsing rates: 22–50% of patients suffer
recurrent episodes within 6 months after recovery (World Health Organization, 2004). It is
associated with compromised quality of life, increased health care costs, and greater risk for a
widespread medical conditions, particularly coronary heart disease.
Major depressive disorder is common in Parkinson’s disease (PD), a progressively debilitating
neurological disorder affecting over 1 million individuals in the United States and approximately
6 millions worldwide. PD is considered as a movement disorder characterized by four cardinal
motor symptoms: tremor, muscle rigidity, motor slowness and postural instability. However, most
patients do also experience non-motor manifestations (Chaudhuri et al., 2006) such as cognitive
or emotional disturbances that significantly contribute to their disability (Weintraub et al., 2004).
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The prevalence of major depressive disorder in patients
with PD (PD-dep) has not been well established. The average
prevalence of clinically significant depressive symptoms was
calculated to be close to 35% (Reijnders et al., 2008). However,
estimates may vary according to different factors such as age
and disease stage. High prevalence was reported in patients with
younger age of diagnosis, peaking at onset or in the advanced
stages (Schrag et al., 2003).
PD-dep has been speculated to have some distinctive features
when compared with major depressive disorder in non-PD
patients, including relatively high levels of anxiety, preservation
of short-term memory and no association with severity of
motor symptoms. In addition, irritability, sadness, dysphoria,
pessimism and suicide ideation are more common in PD-dep
whereas feelings of failure, self-blame, guilt and real suicide are
less frequent (Burn, 2002).
Major depressive disorder has been shown to lead to
increased disability in patients with PD, affecting activities
of daily living, health-related quality of life, and functional
status (Ravina et al., 2007). Indeed, some of the daily life
impairments are strongly related to the inability to overcome
depressive symptoms (Weintraub et al., 2004). In addition,
PD-dep negatively impacts motor and cognitive abilities (Marsh,
2013). However, despite their major repercussion, affective
disturbances in PD have received less attention compared to
motor and cognitive dysfunctions.
THE BIOCHEMICAL MODEL OF
DEPRESSION IN PD
The etiology of PD-dep is not clear. According to the biochemical
model, PD-dep would be secondary to neurobiological changes
that result from the degenerative process, namely a decrease in
monoamine levels (Mayeux et al., 1984; Chan-Palay and Asan,
1989; Remy et al., 2005).
The hallmark of PD is a loss of dopaminergic neurons
in the ventrolateral tiers of the substantia nigra pars
compacta in midbrain (Fearnley and Lees, 1991) leading
to a deficiency of dopaminergic terminals in the posterior
‘‘motor’’ aspects of the striatum (Kish et al., 1988). This
results into motor disturbances such as movement slowness
and increased muscle tone. The midbrain also contains a
distinct cluster of dopaminergic neurons lying in the ventral
tegmental area (VTA) that may be affected in PD. These
neurons project to cognitive and limbic areas. The targets
of the mesocortical ‘‘cognitive’’ pathway are the anterior
cingulate, entorhinal and prefrontal cortices whereas the
mesolimbic ‘‘reward’’ pathway is directed to to the ventral
striatum, bed nucleus of the stria terminalis, hippocampus,
amygdala and septum (Dunlop and Nemeroff, 2007).
Therefore, by affecting these nodes of the limbic and cognitive
systems, dopaminergic deficiency is likely to be involved in
PD-dep pathophysiology. This is supported by some clinical
observations: for instance, the occurrence of depressive
symptoms is sometimes specifically associated with off
dopaminergic states whereas dopamine agonists such as
pramipexole (i.e., a D2/D3 receptor agonist) have shown
antidepressant effects regardless of motor improvement
(Rektorová et al., 2003).
However, the assumption that basal ganglia-cortical loops
are organized into distinct functional zones has been challenged.
A relationship between the motor and the limbic networks
is supported by deep brain stimulation (DBS) studies.
Thus, although high-frequency electrical stimulation into
the subthalamic nucleus (STN) is able to improve motor
symptoms in advanced PD, it can also either improve or
induce depressive symptoms (Takeshita et al., 2005; Temel
et al., 2009). Additionally, information processing in brain
networks depends on the pattern of activity across different
frequency bands. While beta activity may serve as a channel
for motor processing in PD, existing evidence supports
the hypothesis that emotion processing is associated with
alpha activity in basal ganglia cortical networks. Indeed,
alpha activity is modulated by dopaminergic therapy and
emotional state in PD (Kühn et al., 2005; Huebl et al.,
2014) and is also correlated with symptom severity in
severely depressed patients without PD (Neumann et al.,
2014).
The relationship between dopamine signaling, synaptic
plasticity and depression is complex. In their review, Lavergne
and Jay (2010) presented evidence suggesting that major
depressive disorder is associated with decreased dopamine
signaling and decreased synaptic plasticity in several brain
regions, especially in the prefrontal cortex. In addition, dopamine
release in the prefrontal cortex was observed in response to most
pharmacological treatments, independently of their mechanism
of action. They proposed a model where major depressive
disorder is a state of dopaminergic-induced synaptic depression
in the frontal cortex while optimal dopamine transmission
would restore synaptic potentiation. According to the model,
this relationship is not linear but rather follows an inverted
U curve: too little or too much dopamine signaling in the
frontal cortex would be associated to a state of clinical and
synaptic depression. In PD, there is evidence supporting an
inverted U shape relationship between frontal lobe functions
and dopaminergic states regarding cognition (Cools et al., 2001).
However, to the best of our knowledge, this model has never been
explicitly tested for PD-dep.
In PD, neurodegenerative processes not only affect dopamine
neurotransmission but also other monoaminergic neurons
including noradrenergic and serotonergic systems, which may
also play a role in the pathophysiology (Lang and Lozano, 1998).
Supporting this view, a positron emission tomography (PET)
study using a noradrenergic radiotracer found that PD-dep was
associated with a reduced uptake in the limbic system (Remy
et al., 2005). In addition, serotonergic neuron loss within the
raphe nuclei has also been demonstrated in PD (Paulus and
Jellinger, 1991).
However, a direct causal relationship between
major depressive disorder and disrupted monoamine
neurotransmission has been questionned since serotonin
and catecholamine depletion do not affect mood in healthy
subjects (Ruhé et al., 2007). In PD, the monoamine hypothesis
is also unable to adequately explain the low rate of responders
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and the delayed mood improvement after antidepressant
administration in responders. Moreover, it cannot sufficiently
explain the complex manifestations of major depressive disorder.
For instance, the relationship between PD severity and major
depressive disorder follows a bimodal distribution curve rather
than being linear: the first peak is more common during the
early stages and the second one during the advanced stages of the
disease. This suggests a potential reactive mechanism in response
to the initial diagnosis and to the later a loss of functional
independence secondary to physical deterioration (Cummings,
1992; Veazey et al., 2005).
TREATMENT STRATEGY BASED ON THE
BIOCHEMICAL MODEL
The most widely used strategy for the treatment of PD-dep is
based on the biochemical model. Antidepressant medication
remains as the mainstay in the treatment of PD-dep. Agents
used to increase monoamine levels have been long time
considered as the first line choice of PD-dep treatment.
However, antidepressants seem to be less effective than
expected or have intolerable adverse effects in many PD
patients with major depresive disorder, including worsening
of some motor symptoms, visual hallucinations, delusions
and orthostatic hypotension, as well as several important
drug interactions (Veazey et al., 2005; Wensel et al.,
2005). Although selective serotonin reuptake inhibitors
(i.e., SSRIs) are commonly prescribed to treat PD-dep,
there is insufficient evidence to conclude on their efficacy,
according to an evidence-based medicine review (Seppi
et al., 2011). Additionally, SSRIs may have an antagonistic
effect on dopamine, sometimes leading to a worsening
of motor symptoms (Wensel et al., 2005). As already
mentioned above, another pharmacological strategy involves
the administration of D2/D3 receptor agonists (Barone
et al., 2010; Seppi et al., 2011). However, their efficacy
is questionable because of inconsistent results (Liu et al.,
2013). The efficacy of other antidepressants such as tricyclic
agents has not been definitely established but based on actual
evidence, they are considered as being ‘‘likely efficacious’’
(Seppi et al., 2011).
For all these reasons, non-pharmacological strategies are
mandatory in the treatment of PD-dep either to replace or to
potentiate the beneficial effects of drugs.
THE NETWORK MODEL OF DEPRESSION
IN PD
Although the biochemical hypothesis for depression has
dominated the scientific opinion for decades (Schildkraut,
1965), an alternative hypothesis has been recently proposed:
the network hypothesis. According to this model, mood
disorders reflect, at least in part, maladaptive neuronal plasticity
in mood relevant networks, namely the inability of cortico-
limbic circuits—whose key nodes are the prefrontal cortex,
the amygdala and the hippocampus—to appropriately adjust
their microstructure and function to some environmental
experiences (Castrén, 2005, 2013). According to the network
hypothesis, problems in information processing within neural
networks, rather than changes in chemical balance, might
underlie major depressive disorder. The therapeutic effect of
antidepressant drugs might operate through a reactivation of an
‘‘early-life plasticity process’’, that involves environment-
driven recruitment of appropriate network connections
(Castrén, 2005). Therefore, the way these networks activate
and reorganize is dependent of the environment. This suggests
that pharmacological treatments alone are not sufficient for
improving mood and therefore require to be combined with
appropriate rehabilitation, such as cognitive and behavioral
therapy (CBT), that guides the plastic networks (Castrén,
2013).
TREATMENT STRATEGY BASED ON THE
NETWORK MODEL OF DEPRESSION
We hypothesize here that efficient environment-driven network
reorganization could be achieved by combining three kind of
interventions: non-invasive brain stimulation (NIBS), CBT and
physical training (Krystal, 2007; Castrén and Rantamäki, 2010;
Figures 1, 2).
NIBS
Electrical brain stimulation has a long history in the treatment
of refractory depression. Electroconvulsive therapy (ECT)
was introduced as a powerful therapeutic option for severe
psychiatric disorders about 70 years ago. Since the early 50’s,
ECT has been widely used with antidepressant purposes and is
still considered as the most effective acute treatment for major
depressive disorder (Kho et al., 2003; standardized effect size:
−0.91, UK ECT Review Group, 2003). ECT is a procedure
in which administration of an electrical current through the
brain of anesthetized patients induces a generalized seizure
that produces changes in brain functions, especially mood, by
acting over frontotemporal circuits (Anderson and Fergusson,
2013). However, ECT has some important adverse effects such
asystolia, tachycardia, delirium, agitation, memory impairment
and transient neurological motor deficit which limit its usage.
Transcranial magnetic stimulation (TMS) has been touted as
a safe alternative to ECT. TMS is a non-invasive technique that
uses electromagnetic induction to generate weak electric currents
in the stimulated cortex, modifying cortical activity (Rossi et al.,
2009). Repetitive TMS (rTMS) is capable of producing a long-
lasting modulation of cortical activity. From a neurobiological
point of view, rTMS has been proposed to promote synaptic
plasticity, an effect described as long term potentiation (LTP)
or depression LTD. The effects of rTMS propagate beyond the
stimulation site to impact a widely distributed set of connected
brain regions (i.e., a brain network). Evidence suggests that these
modulations are relevant in the therapeutic response (Lefaucheur
et al., 2014).
In patients with major depressive disorder, many rTMS
studies have been designed to stimulate the left prefrontal
cortex with high-frequency (i.e., >1 Hz) stimulation during
several daily sessions to achieve a long-lasting therapeutic
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FIGURE 1 | This figure was adapted from Castrén (2005). The network model of depression suggests that pharmacological treatments alone are not sufficient
for improving mood and need to be combined with appropriate (neuro)rehabilitation to support the reorganization of plastic networks. With the permission of Nature
Publishing Group (http://www.nature.com/npg_/index_npg.html).
FIGURE 2 | Hypothesis about the direct and indirect effects of a combined therapeutic strategy for depression, highlighting the interest of a
multidisciplinary approach for treating PD patients.
effect. The rationale for the use of lateralized rTMS is
based on the hypothesis that mood disorders may result
from a relative imbalance between left and right frontal
lobe activity (Davidson et al., 2002). According to this
hypothesis, major depressive disorder is associated with a
decreased activation of the left frontal lobe, which is normally
involved in approach-related, appetitive behaviors. This
imbalance between left and right frontal lobe functions
would negatively impact onto prefrontal-limbic networks,
composed of interconnected brain areas including the
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anterior cingulate cortex (ACC), the amygdala and the
hippocampus (Bennett, 2011). The lateralized hypothesis
of depression is supported by lesional and neuroimaging
studies. Indeed, depressive symptoms are more frequent in
left brain-damaged patients (Gainotti, 1972). More recent
studies showed hypofunctioning left prefrontal cortex in
people with major depressive disorder (Fitzgerald et al.,
2006; Steele et al., 2007). High frequency rTMS over the left
dorsolateral prefrontal cortex (DLPFC) can also influence
distant brain regions that are compromised in major depressive
disorder suggesting that its therapeutic effect may operate by
modulating functional connectivity in broad cortical networks,
notably the default mode and the central executive networks
(Liston et al., 2014).
A recent meta-review of 15 meta-analyses concluded that
DLPFC rTMS is an effective and safe brain stimulation
technique for the treatment of medication refractory depression,
with moderate to large effect size (i.e., weighted mean
effect size from 0.39 to 0.89; Dell’osso et al., 2011). High
frequency rTMS is now approved by the Food and Drug
Administration (FDA) ‘‘to treat the symptoms of major
depressive disorder without inducing seizure in patients who
have failed at least one antidepressant medication and are
currently not on any antidepressant therapy’’1. The response
rate is approximately 50% (Connolly et al., 2012) and has
been reported to remain stable even after 6 months (Concerto
et al., 2015). One limitation of rTMS in major depressive
disorder is the inability to identify the optimal stimulation
site in the left DLPFC. It is ususally recommended to
stimulate a spot 5 cm anterior to the motor cortex along
the curvature of the scalp (i.e., O’Reardon et al., 2007).
It is not surprising that this technique leads to variability
in both the stimulated region and therapeutic response
(Herwig et al., 2001; Fitzgerald, 2009; Herbsman et al.,
2009). Recently, new targets are being investigated. Four new
potential regions have been identified as candidates for rTMS
in major depressive disorder: dorsomedial prefrontal cortex
(DMPFC), frontopolar cortex (FPC), ventromedial prefrontal
cortex (VMPFC), and ventrolateral prefrontal cortex (VLPFC;
Downar and Daskalakis, 2013). The DMPFC is perhaps
the more promising target because of the link between
lesions of this region and severe depression. In addition, a
pioneer study has already shown the potential effectiveness
of stimulating DMPFC for treating major depressive disorder
(Bakker et al., 2015).
Moreover, the evidence that major depressive disorder is
associated with an imbalance between hemisphere functioning
is exclusively correlative and results are not always consistent
across studies (Fitzgerald et al., 2006). A causal relationship
between laterality and major depressive disorder is partially
supported by previous TMS studies evaluating the effects of
left and right rTMS (Chen et al., 2013). However, these
studies compared high-frequency left to low-frequency right
rTMS. Therefore, laterality is a factor that should be addressed,
1http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?
fr=882.5805
especially by comparing the effect of different rTMS protocols
(inhibitory-excitatory/Left-right DLPFC) on clinical and brain
responses in major depressive disorder.
In PD, NIBS has first been tested on motor symptoms.
Indeed, when applied over the primary motor cortex, both rTMS
and transcranial direct current stimulation (tDCS) are able to
improve motor functions, as measured by the Unified PD Rating
Scale (UPDRS-III; Broeder et al., 2015;Wagle Shukla et al., 2015).
rTMS has been claimed to be effective on improving PD-
dep when applied over the left DLPFC (Fregni et al., 2004;
Epstein et al., 2007). Fregni et al. (2004) reported a 41%-
proportion of treatment-responders (with 50% reduction in
the Hamilton Rating scale) with 15 Hz-rTMS for 10 days
during 2 weeks. A randomized double-blind controlled trial
using 5 Hz left DLPFC rTMS for 10 days in patients with
PD-dep showed a significant decrease of 44% in the Beck
Depression Inventory score lasting at least 30 days after
the end of the stimulation protocol (Pal et al., 2010). A
recent meta-analysis evaluating the effect of DLPFC rTMS
on PD-dep has reaveled a significant improvement in the
Hamilton Depression Rating Scale (HDRS) compared with
sham-rTMS (standard mean difference = −0.88) and suggested
a similar antidepressant efficacy as the one obtained with SSRIs
(Xie et al., 2015).
CBT
Another environment-driven approach for the treatment of
major depressive disorder is CBT. This method was first
developed by Beck’s (1995) and is based on a cognitive model
of the relationship between how we think (cognition), how
we feel (emotion) and how we act (behavior). Beck et al.
(1979) proposed that disturbances in information processing
are key features in major depressive disorder. According to this
model, people with major depressive disorder hold negative
core beliefs developed during childhood, which are re-activated
by life events and produce automatically generated thoughts
about the self, the world and the future. Therefore, CBT
consists in helping patients to evaluate their thinking in a
more realistic and adaptive way in order to modify negative
automatic thoughts (Beck et al., 1979). CBT includes three main
phases: a psychoeducation phase, a behavioral activation phase
and a cognitive restructuring phase. The psychoeducation phase
is related to teaching the cognitive model and understanding
the dysfunctional information processing in major depressive
disorder. After acceptance of the model and after having
reviewed daily behaviors, proposals for planning new and
rewarding activities are suggested. The psychotherapist and
patients can afterwards work together in the identification
of negative automatic thoughts that maintain the patient in
the spiral of depression in order to better change them into
more balanced and realistic thoughts. Therefore, CBT for major
depressive disorder could be seen as a cognitive training for
the learning of new skills regarding information processing.
CBT is effective in treating major depressive disorder in adults
(Hofmann et al., 2013), with a medium effect size of −0.69
to −0.42 (Cohen’s d) after correction for publication bias
(Cuijpers et al., 2010). A meta-analysis reported a response rate
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between 57 and 87% in major depressive disorder (Leichsenring,
2001).
The beneficial effects of CBT in major depressive disorder
have been associated with neuroplastic changes in relevant
brain networks. (Goldapple et al., 2004; Dichter et al., 2010;
Ritchey et al., 2011; Yoshimura et al., 2014). For instance,
Ritchey et al. (2011), using functional magnetic resonance
imaging (fMRI), showed that one weekly session of CBT
during 30.3 weeks in average, led to an increased activity in
the prefrontal cortex of depressed patients during emotion
processing. In another study, Goldapple et al. (2004) showed
cerebral glucose uptake changes in the cortico-limbic pathway,
notably an increased metabolism in the hippocampus and
a decreased metabolism in the DLPFC following CBT. The
effects on brain structure and function have also been reported
after CBT interventions in other psychiatric conditions. In
a study involving people with chronic fatigue syndrome, de
Lange et al. (2008) reported increased gray matter volume
bilaterally in the DLPFC after approximately 16 sessions
of therapy. Thus, an individualized tailored psycho-cognitive
training approach such as cognitive restructuring could induce
substantial and stable brain changes through neuroplastic
mechanisms finally resulting in emotional and behavioral
improvements.
CBT has received little scientific attention in PD patients.
Only a few studies examined the effectiveness of CBT for PD-dep
(e.g., Farabaugh et al., 2010; Dobkin et al., 2011; Yang et al., 2012).
In a ten-session randomized controlled trial of CBT for PD-
dep that included some patients taking antidepressants, symptom
severity improved by 56% relative to 8% for the control group
(Dobkin et al., 2011). Additionally, there were significantly more
responders in the CBT group (i.e., number needed to treat 2.1;
absolute risk reduction 48%), and large effect sizes were observed
on all depression outcome measures.
Only one study examined the effect of psychological
intervention (i.e., Mindfulness based intervention) on brain
plasticty in PD patients (Pickut et al., 2013). Mindfulness based
intervention is considered to belong to the third wave of CBT
with the core goal of developing metacognitive awareness which
is the ability to experience cognitions and emotions as mental
events that pass through the mind with a compassionate non-
judgmental stance. Therefore, mindfulness could be viewed as a
kind of attention training (Jha et al., 2007). After mindfulness-
based intervention, there was an increased gray matter density
in key limbic regions, i.e., the amygdala and hippocampus.
This finding suggests that psychotherapeutic interventions in PD
patients have also the potential to influence cortical plasticity.
Physical Exercise
According to the network hypothesis of depression, physical
exercise can be viewed as an environmental stimulation adjuvant
to CBT and NIBS, that guides efficient neural network
reorganization (Figure 1).
The indication of regular physical activity as a therapeutic
strategy in PD-dep is mainly supported by the positive effects
observed in depressed people without PD. A meta-analysis
examined the effects of exercise on depression/depressive
symptoms in 58 randomized controlled trials (n = 2982).
An overall effect size of −0.80 (Hedges’ g) indicated that
participants in the exercise treatment group had significantly
lower depression scores than those receiving the control
treatment or no-treatment (Rethorst et al., 2009). The same
authors also analyzed the moderating variables of exercise
programs (i.e., duration, exercise type, frequency and intensity).
Programs lasting 10–16 weeks resulted in stronger effects than
shorter interventions. The exercise programs that combined
erobic and resistance exercises resulted in larger effects than
erobic or resistance training alone. It is noteworthy that
converging evidence support the beneficial effect of physical
activity on anxiety, which is frequently associated with
depression (Wipfli et al., 2008). In addition, a few studies showed
that a tailored exercise program is an effective way to improve
performance of daily activities and both motor and non-motor
symptoms, such as mood, in PD patients (i.e., decrease in Beck
Depression Inventory-II score; Cugusi et al., 2014, 2015; Lattari
et al., 2014).
Several hypotheses that involve biochemical, physiological,
and psychosocial mechanisms have been offered to account
for the effect of exercise on major depressive disorder. At a
psychological level, physical exercise can increase perception and
awareness of the body and physical self, with a positive impact on
self-esteem and therefore fewer feelings of depression (Knapen
et al., 2005; Eriksson and Gard, 2011). At a neurobiological
level, erobic exercise triggers plasticity-related changes in the
brain, such as synaptogenesis, enhanced glucose utilization and
neurogenesis (Speelman et al., 2011). In PD, erobic exercise
may be beneficial in the improvement of motor, cognitive
and emotional functioning by enhancing neuroplasticity and
reducing neuroinflammation (Speelman et al., 2011).
TOWARDS A MULTIDIMENSIONAL
APPROACH FOR TREATING PD-dep
Emotion, movement and cognition are linked and are mediated
through fronto-striatal loops. The prefrontal cortex is a central
cerebral region that provides top-down regulation of attention,
inhibition, motivation, and emotion through connections with
subcortical structures (Tekin and Cummings, 2002). There
are three main regions involved in major depressive disorder
situated in the anterior part of the frontal lobe: the DLPFC, the
orbritofrontal cortex (OFC) and the ACC. These cortical areas
belong to three distinct fronto-striatal circuits which mediate
cognitive functioning, motivation and emotion regulation
(Bonelli and Cummings, 2007). The DLPFC, which is a key
region in major depressive disorder, is presumed to be mainly
related to cognitive processing. Impaired DLPFC functioning
can result in cognitive biases such as attention allocation toward
negative stimuli and distorted information processing, but also
more global cognitive deficits such as attention, workingmemory
and executive dysfunctions (Murrough et al., 2011). According
to Beck et al. (1979) cognitive model, distorted automatic
cognitions negatively influence mood and behavior. Therefore,
proper top-down regulation of emotion might be achieved
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through normalization of DLPFC functioning by combining
CBT, cognitive training and NIBS.
Although medications and CBT, alone or in combination, are
considered effective treatments for major depressive disorder,
up to 30% of patients show no improvement or only a
partial response. Previous reports support the efficacy and good
tolerability of rTMS in the treatment ofmajor depressive disorder
(Horvath et al., 2010). So far however, no study has assessed the
effect of combining brain stimulation with CBT in the treatment
of PD-dep, even if both methods are able to induce changes in
prefrontal activity (Cardoso et al., 2008; Ritchey et al., 2011).
Only two case-report studies of feasibility have tested the effect
of NIBS combined with CBT on patients with treatment-resistant
major depressive disorder (Vedeniapin et al., 2010; D’Urso et al.,
2013). D’Urso et al. (2013) applied daily tDCS, another NIBS
technique, during 2 weeks in addition to CBT in a 52-year old
woman with severe and chronic major depressive disorder. This
synergistic treatment induced substantial improvement in the
HDRS with complete remission of symptoms, which remained
stable over 12 months. The other available report (Vedeniapin
et al., 2010) examined the effect of CBT together with left
prefrontal cortex rTMS on a 26 year old female student with
resistant major depressive disorder. After a 14-week-treatment
with 3 weekly rTMS sessions and a total of 14 CBT sessions,
the patient showed reduction in symptoms with a remission
that lasted up to 3 months after the end of the intervention.
However, the precise contribution of each treatment cannot
be separetely accounted. For this reason, 4-arm, randomized
controlled trials are needed to test the hypothesis of a synergistic
effect of nonpharmachological strategies in the treatment of
PD-dep (Group 1: sham rTMS + placebo psychotherapy or
waiting list condition; Group 2: rTMS + placebo psychotherapy
or waiting list condition; Group 3: CBT + sham rTMS;
Group 4: rTMS + CBT). A recent randomized double-blinded
trial lead the way for future controlled studies, by combining
cognitive training with simultaneous DLPFC tDCS in PD
patients with mild cognitive impairments (Biundo et al.,
2015).
CONCLUSION
In summary, we reviewed here the importance of treating PD-
dep because of its negative direct and indirect influence on
quality of life and mobility. According to the network hypothesis
of depression, we suggest a new type of combined therapy
for treating PD-dep, focused on the optimization of activity-
dependent plasticity in the prefrontal cortex, especially DLPFC
rTMS and CBT (Figure 2). This approach could be first focused
on behavioral and cognitive activation by practicing physical
activity, enhancing social interactions and intellectual activities
and secondly on cognitive restructuring of negative automatic
thoughts. This kind of combined therapymight have additive and
synergistic influences on mood through an increased cortico-
limbic stimulation-induced plasticity.
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